A Biomimetic Microparticle Disrupting the Intracellular/Extracellular pH Homeostasis of Tumor Cells for Cancer Chemo-Immunotherapy
Source abstract
Abstract
The intracellular/extracellular pH balance is crucial for tumor cells to maintain survival and proliferation. Therefore, a variety of strategies have been developed to disrupt this balance for efficient tumor growth suppression. However, most of them focus on either exacerbating intracellular acidity or alleviating extracellular acidification, with a lack of approaches that interfere with both intracellular and extracellular pH. Herein, we developed a biomimetic tumor cell-derived microparticle for tumor-targeted codelivery of syrosingopine (Syr) and doxorubicin prodrug (Dox-EMCH). Syr can inhibit lactate efflux, disrupting pH homeostasis inside and outside the tumor cells. The increased intracellular acidity activates Dox-EMCH to induce immunogenic cell death, while the alleviated acidity outside tumor cells modulates the immunosuppressive tumor microenvironment (TME) by restoring the activities of cytotoxic T lymphocytes and natural killer cells, promoting M1-like macrophage polarization, and inhibiting regulatory T cells. As a result, the biomimetic microparticles initiate orchestrated chemotherapy and immunotherapy for effective tumor suppression by disrupting the intracellular and extracellular pH balance in tumor tissues.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Life Science and Technology
Harbin Institute of Technology
Funding
Harbin Institute of Technology · Natural Science Foundation of Heilongjiang Province · Heilongjiang Postdoctoral Science Foundation
References (45)
Show source-provided references
1. 10.1038/s42255-023-00927-310.1038/s42255-023-00927-3 ↗
2. 10.1101/cshperspect.a04153210.1101/cshperspect.a041532 ↗
3. 10.1016/j.drup.2018.03.00110.1016/j.drup.2018.03.001 ↗
4. 10.1021/jacs.2c0766910.1021/jacs.2c07669 ↗
5. 10.1016/j.trecan.2025.09.00610.1016/j.trecan.2025.09.006 ↗
6. 10.1016/j.molmet.2019.07.00610.1016/j.molmet.2019.07.006 ↗
7. 10.1158/0008-5472.CAN-17-076410.1158/0008-5472.CAN-17-0764 ↗
8. 10.1002/adhm.20200054910.1002/adhm.202000549 ↗
9. 10.1039/D2BM00650B10.1039/D2BM00650B ↗
10. 10.1021/acsnano.4c0721310.1021/acsnano.4c07213 ↗
11. 10.1021/acsami.2c0553310.1021/acsami.2c05533 ↗
12. 10.1016/j.mattod.2023.07.00310.1016/j.mattod.2023.07.003 ↗
13. 10.3389/fonc.2022.97915410.3389/fonc.2022.979154 ↗
14. 10.3390/cancers1204089810.3390/cancers12040898 ↗
15. 10.1016/j.apsb.2021.01.01210.1016/j.apsb.2021.01.012 ↗
16. 10.2147/IJN.S36618710.2147/IJN.S366187 ↗
17. 10.1002/adfm.20240092910.1002/adfm.202400929 ↗
18. 10.1002/anie.20210758810.1002/anie.202107588 ↗
19. 10.1021/acsbiomaterials.9b0043610.1021/acsbiomaterials.9b00436 ↗
20. 10.1111/bph.1277310.1111/bph.12773 ↗
21. 10.1172/JCI18887210.1172/JCI188872 ↗
22. 10.1016/j.jconrel.2019.10.04110.1016/j.jconrel.2019.10.041 ↗
23. 10.1007/s00262-018-2195-z10.1007/s00262-018-2195-z ↗
24. 10.3390/cells1322192410.3390/cells13221924 ↗
25. 10.1002/advs.20230068610.1002/advs.202300686 ↗
26. 10.1002/adma.20220795110.1002/adma.202207951 ↗
27. 10.1002/adfm.20242184910.1002/adfm.202421849 ↗
28. 10.1002/adma.20230551210.1002/adma.202305512 ↗
29. 10.1016/j.cej.2024.15257410.1016/j.cej.2024.152574 ↗
30. 10.1002/adfm.20240324510.1002/adfm.202403245 ↗
31. 10.1021/acs.nanolett.3c0038310.1021/acs.nanolett.3c00383 ↗
32. 10.1126/sciadv.aay978910.1126/sciadv.aay9789 ↗
33. 10.1002/anie.20210925810.1002/anie.202109258 ↗
34. 10.1021/acsnano.2c0687110.1021/acsnano.2c06871 ↗
35. 10.2147/CMAR.S42177110.2147/CMAR.S421771 ↗
36. 10.1002/advs.20220173410.1002/advs.202201734 ↗
37. 10.1039/D1NR05512G10.1039/D1NR05512G ↗
38. 10.1002/advs.20241522710.1002/advs.202415227 ↗
39. 10.1016/j.ccell.2023.02.01410.1016/j.ccell.2023.02.014 ↗
40. 10.1016/j.cej.2024.15728810.1016/j.cej.2024.157288 ↗
41. 10.1016/j.trecan.2022.06.00810.1016/j.trecan.2022.06.008 ↗
42. 10.1002/ijc.3218310.1002/ijc.32183 ↗
43. 10.1053/j.semdp.2017.11.00910.1053/j.semdp.2017.11.009 ↗
44. 10.1007/s13238-020-00707-910.1007/s13238-020-00707-9 ↗
45. 10.1146/annurev.immunol.22.012703.10470210.1146/annurev.immunol.22.012703.104702 ↗